CASI pharmaceuticals, Inc.
CASI pharmaceuticals, Inc.
Explore linked clinical trials.2 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Two Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated Rejection (ABMR). | Antibody Mediated Rejection | Recruiting | Phase 1 / Phase 2 | 2026-07-22 | NCT07641426 | |
| A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia | Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Skin Manifestations, blood coagulation disease, hematologic disorder, purpura | Recruiting | Phase 1 / Phase 2 | 2025-06-12 | NCT07017725 |